NASDAQ · ALIM
Healthcare · Drug Manufacturers - Specialty & Generic
$5.54
Down-$0.01 (-0.18%)
Updated Aug 15, 2026, 3:20 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ALIM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ALIM.
ALIM research
Company profile and research snapshot.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2024 | Alliance Global Partners | Neutral | — |
| Jun 25, 2024 | Maxim Group | Hold | — |
| Jun 25, 2024 | HC Wainwright & Co. | Neutral | — |
| May 16, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 16, 2024
ANI Pharmaceuticals has completed the acquisition of Alimera Sciences, strengthening its Rare Disease segment and expanding its ophthalmology portfolio. The transaction is expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and be substantially accretive thereafter.
Benzinga · Sep 11, 2024
ANI Pharmaceuticals and Alimera Sciences have announced the closing date of their previously announced merger for September 16, 2024. The merger is subject to certain risks and forward-looking statements.
Benzinga · Sep 10, 2024
ANI Pharmaceuticals provided an update on the status of its acquisition of Alimera Sciences, stating that they continue to work towards closing the deal and expect to resolve any delays related to closing conditions promptly.
GlobeNewswire Inc. · Jul 8, 2024
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to the proposed sales of Alimera Sciences, Morphic Holding, and Avangrid.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALIM.
No results
No recent SID articles mention ALIM.
